Navigation Links
Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate
Date:5/11/2011

LOS ANGELES, May 11, 2011 /PRNewswire/ -- Instacare Corp. (OTCQB: ISCR), the exclusive provider of the Shasta Genstrip, a revolutionary diagnostic product targeted at the $20 billion diabetes care marketplace, a leading provider of prescription diagnostics and home testing products for the chronically ill, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that its Board of Directors has met regarding the 2nd confidential proposal received from the NASDAQ traded company (the "Company") recently mentioned in a Press Release, and has for the second time rejected the Merger Offer as inadequate in providing fair value to Instacare shareholders.

The Board of Directors of Instacare Corp. did find more merit in the latest proposal and thus asked Chairman Robert Jagunich to prepare a counter proposal on behalf of the Board.  Mr. Jagunich has completed the counter offer and sent it to the Company.

Keith Berman, CFO and Secretary of Instacare Corp. commented, "Although the current merger proposal offers Instacare shareholders more value and better terms than the first offer, and although this latest proposal offers a substantial premium to the company's current share price, it is the Board's belief that, based on the Walling reports of January 24 and March 2 and Walling's update expected prior to May 20, the company offers more value to its shareholders, by remaining independent."

Mr. Berman continued, "Given the near term release of Genstrip and an advertising and branding campaign slated to begin this month, as well as discussions we are in with other companies, Instacare intends to engage an investment bank to evaluate all offers and explore possible strategic alternatives."

For more information about Instacare Corp., Pharma Tech Solutions, Inc. and/or its revolutionary MD@Hand cell phone centric technologies, please visit the Instacare web site

SOURCE Instacare Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. instaCare Corp. Continues Turnaround, Reports 58% Revenues Increase for First Three Quarters
2. Instacare Corp. Board of Directors Sets Growth Plans for 2010
3. Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products
4. InstaCare Corp. to Announce Guidance on Its Genstrip Product Line on January 10, 2011
5. InstaCare Corp. Announces 2011 Genstrip Guidance Report Penned by William Walling, CFA
6. InstaCare Files Full Utility Patent for MD@Hand & MD@Work Technologies
7. InstaCare Announces Receipt of Technology and Patent Value Analysis Penned by Joseph Wolf, Ph.D and William Walling, CFA
8. InstaCare Extends MD@Hand & MD@Work Mobile EMR/EHR Technology to Smart Pad Systems
9. InstaCare Announces Ready for Market MD@Detail Mobile Health Media System for Pharmaceutical e-Detailing
10. InstaCare Subsidiary Signs New Agreement for Expanded Management and Sales of Shasta Genstrip Into the $20 Billion Worldwide Diabetes Testing Market
11. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 ... Pharmaceuticals, Inc. today announced that the Committee for Medicinal ... Agency (EMA) has adopted a positive opinion for the ... of adult men with Peyronie,s disease with a palpable ... at the start of therapy. The use ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Company remains committed to speeding innovation ... pipeline boasts 70 potential medicines in clinical development, including 33 in ... ten potential new medicines in Phase III by the end of ... such as neuroscience, diabetes and oncology, as well as new areas ...
... MISSISSAUGA, Ontario, June 30, 2011 Valeant Pharmaceuticals ... VRX) announced today that its subsidiary, Valeant International ... acquire rights to both Elidel (pimecrolimus 1% cream) ... Meda, an international specialty pharmaceutical company (listed on ...
Cached Medicine Technology:Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 2Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 3
(Date:12/26/2014)... England (PRWEB) December 26, 2014 The ... take place March 24-28, 2015 in Rome, Italy and ... line-up includes workshops on a wide variety ... as well as peak performance training in athletes. The ... around the world. , Biofeedback monitoring allows clients to ...
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... about the brain affect the course of a criminal trial, ... a sentence? This was the topic of ... for Neuroscience,s "Neuroscience 2011." Titled "The Brain on Trial: Neuroscience ... neuroscience are both challenging and assisting the judicial system. To ...
... SUNDAY, Dec. 11 (HealthDay News) -- A drug called ... cell anemia can also help young children with the disease, ... younger than 4 years old who took the medication had ... with fever and need for transfusions, the study found. ...
... leukemia patients, own infection-fighting cells appears to protect ... with fludarabine-based chemotherapy, according to new research from ... of Pennsylvania. The new process is a step ... from the commonly prescribed drug, which improves progression-free ...
... SAN DIEGO - A new, targeted approach to treating ... Phase I/II clinical trial for patients with relapsed or ... of the American Society of Hematology. "PCI-32765, one ... cell receptor inhibitors, has shown impressive potential in this ...
... FRIDAY, Dec. 9 (HealthDay News) -- Flu vaccination is easy ... your health during the flu season, but too few Americans ... off concerns about the flu, yet every year it strikes ... to the hospital and killing thousands," Dr. Thomas Slama, president ...
... Terrorist attacks with chemical weapons are a real possibility, ... access journal, Journal of Pharmacy Practice , published by ... how to treat those who have been exposed, pharmacists are ... potential chemical weapons attack. Chemical weapons act on their ...
Cached Medicine News:Health News:The brain on trial 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 3Health News:Penn researchers repair immune system in leukemia patients following chemotherapy 2Health News:Penn researchers repair immune system in leukemia patients following chemotherapy 3Health News:B cell receptor inhibitor causes chronic lymphocytic leukemia remission 2Health News:Americans Encouraged to Get Flu Vaccine 2Health News:Pharmacists crucial in plan for terrorist chemical weapons 2
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle. Designated most popular model or size....
Grooved roller, on which knife oscillates....
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
5 mm small, sharp, protected blade. Angled at 105 degrees. Flat handle. Designated most popular model or size....
Medicine Products: